KalVista Pharmaceuticals (KALV) Non-Current Debt (2015 - 2016)
KalVista Pharmaceuticals recorded quarterly Non-Current Debt of $2.7 million in Q1 2016, down 14.36% quarter-over-quarter from $3.2 million in Q4 2015, and down 20.65% year-over-year from $3.4 million in Q2 2015.
KalVista Pharmaceuticals' Non-Current Debt history runs 2 years deep, the most recent figure standing at $2.7 million for Q1 2016.
- In Q1 2016, Non-Current Debt fell 20.65% year-over-year to $2.7 million; the TTM figure through Mar 2016 stood at $2.7 million (down 20.65% YoY), while the FY2015 annual figure was $3.2 million, changed N/A from the prior year.
- Non-Current Debt came in at $2.7 million for Q1 2016 at KalVista Pharmaceuticals, down from $3.2 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $4.0 million in Q2 2015 to a low of $2.7 million in Q1 2016.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 319.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 105.94 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.99 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2016 | 2.70 Mn |
| Mar 31, 2016 | 2.70 Mn |
| Dec 31, 2015 | 3.15 Mn |
| Dec 31, 2015 | 3.15 Mn |
| Sep 30, 2015 | 3.60 Mn |
| Sep 30, 2015 | 3.60 Mn |
| Jun 30, 2015 | 4.04 Mn |
| Jun 30, 2015 | 4.04 Mn |
| Mar 31, 2015 | 3.40 Mn |
| Mar 31, 2015 | 3.40 Mn |